New hope for young brain cancer patients in Early-Stage trial

NCT ID NCT03749187

Summary

This early-stage study is testing a new two-drug combination (BGB-290 and temozolomide) for adolescents and young adults with specific types of brain tumors that have returned or are newly diagnosed. The main goal is to find the safest dose and understand the side effects. Researchers hope this combination will be more effective at controlling the tumors than current treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.